Doubled dosage of sofosbuvir is expected for inhibiting Zika virus infection | Zendy

Somsri Wiwanitkit | Zendy; Viroj Wiwanitkit | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Doubled dosage of sofosbuvir is expected for inhibiting Zika virus infection

Author(s) -

Somsri Wiwanitkit,

Viroj Wiwanitkit

Publication year - 2017

Publication title -

asian pacific journal of tropical medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.491

H-Index - 52

ISSN - 1995-7645

DOI - 10.1016/j.apjtm.2017.06.012

Subject(s) - sofosbuvir , zika virus , hepatitis c virus , virology , medicine , virus , ribavirin

Sofosbuvir is a new antiviral drug that has been recommended for management of hepatitis C virus (HCV) for a few years. New researches support that sofosbuvir might be useful for the management of Zika virus infection. Based on the pharmacological activity, inhibiting the HCV RNA-dependent RNA polymerase (RdRp or NS5 protein), sofosbuvir is proposed for its effectiveness against Zika virus infection. Here, the authors used a mathematical modelling theoretical approach to predict the expected dosage of sofosbuvir for inhibiting Zika virus infection. Based on the modeling study, if sofosbuvir is assigned for management of Zika virus infection, doubled dosage of the present dosage for hepatitis C management is recommended.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research